Renoprotection with antihypertensive effect by inhibition of rennin - angiotensin system

Hypertension is a common cause of chronic kidney disease (CKD) and even more common sequelae of CKD. It is essential to preserve renal function while controlling blood pressure. There is growing evidence that reduction and normalization of proteinuria is a key treatment goal for renal protection. Several clinical studies, mainly but not exclusively in diabetic patients were reviewed, subsequently suggested that anti-hypertensive agents inhibiting the renin– angiotensin system (RAS), such as angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II type 1 receptor blockers (ARBs), achieved better renoprotection than other anti-hypertensive drugs. Inhibition of the renin-angiotensin system (RAS), either by ACE inhibitors or angiotensin-Receptors blocker (ARB) slows the progression of CKD by reducing the level of proteinuria in the diabetic and nondiabetic CKD resulting in less renal structural damage.